Samso Search Results

Three announcements in eight days — an exclusive data licence with Advara, a ~A$110 million placement, and a strategic investment from Pro Medicus — have left the cardiac-AI company funded, validated, and armed with a hard-to-replicate data asset as it pushes into the United States. Echo IQ Limited (ASX: EIQ) has packed three material announcements into eight days. On 2 July 2026, it executed a binding exclusive data licensing agreement with Advara HeartCare, Australia's largest private cardiovascular provider, securing access to up to one million de-identified echocardiography studies to train its next generation of AI. That followed firm commitments on 1 July for a ~A$110 million placement at A$1.45 per share, and a binding Heads of Agreement on 25 June with global imaging leader Pro Medicus (ASX: PME) for a strategic investment of up to A$20 million and a proposed US reseller partnership. The run of news has landed against one of the ASX's standout share-price performances of 2026: EchoIQ climbed from around A$0.35 in mid-January to an all-time high of A$1.875 on 25 June — roughly a fivefold gain in half a year — for a market capitalisation near A$1 billion. Figure 1: Echo IQ Share Price Chart (Source: Google Finance) At a Glance Item Details Company Echo IQ Limited (ASX: EIQ) — Sydney-based AI and medical-technology company in cardiac diagnostics. Formerly Houston We Have Limited; renamed December 2021. Flagship EchoSolv — an AI clinical decision-support suite that reads the measurements from a standard echocardiogram (without image analysis) to help clinicians detect structural heart disease, led by EchoSolv AS (aortic stenosis) and EchoSolv HF (heart failure). The news Three announcements in eight days: an exclusive Advara data licence (2 July) for up to 1m echo studies; a ~A$110m placement (1 July) at A$1.45/share; and a binding HOA with Pro Medicus (25 June) for up to A$20m plus a proposed US reseller deal. Why it matters The raise and the Pro Medicus investment fund the US commercialisation push and add a blue-chip validator and distribution channel; the Advara licence builds a proprietary data moat for the next generation of EchoSolv products. The raise ~A$110m at A$1.45 (an 8.8% discount to the last traded price on 26 June); 75,862,069 new shares, ~11.5% of current issued capital. Ord Minnett sole lead manager, Morgans co-manager. Settlement 6 July; trading 7 July. Pro Medicus investment Initial A$10m via secured convertible notes; option for a further A$10m on FDA clearance of EchoSolv HF. 12.5% p.a. (compounding daily), 24-month maturity, conversion capped at A$1.05; 0.75 options per note at A$1.35. Data assets Advara HeartCare exclusive licence — 500,000 to 1,000,000 de-identified echocardiography studies (initial 3-year term, HREC-conditional), complementing the existing NEDA longitudinal outcomes database. Regulatory status EchoSolv AS: FDA 510(k) cleared. EchoSolv HF: FDA submission lodged, outcome expected in the near term. Key partners Pro Medicus (proposed US reseller), Mayo Clinic (validation study and distribution pathway), Advara HeartCare (data), plus deployments including Mount Sinai. Leadership Dustin Haines (CEO, US-based, ex-Gilead Sciences); Andrew Grover (Executive Chair). Market performance Standout 2026 performer: ~A$0.35 (mid-January) to an all-time high of A$1.875 (25 June); ~A$1bn market cap; placement struck at A$1.45. (Indicative; moves with the share price.) Next steps Definitive Pro Medicus documentation (coming weeks); placement settlement 6–7 July; HREC approval and data delivery under the Advara licence; FDA outcome on EchoSolv HF. The 60-Second Pitch - Echo IQ Echo IQ is an Australian medical-technology company applying artificial intelligence to cardiology, under the banner “know each heart by its numbers.” Its EchoSolv platform works from the measurements already captured in a standard echocardiogram - delivering measurement-based decision support without image analysis - and returns a risk assessment in seconds, aiming to lift the accuracy and consistency of diagnosis for conditions that are common, serious and chronically underdiagnosed. Because the software reads structured measurements rather than raw imaging, it is built to slot into existing workflows with minimal disruption, and its models were developed on one of the world's largest echocardiographic datasets, exceeding 200 million measurements. The lead product, EchoSolv AS, targets severe aortic stenosis, a valve disease with a high untreated mortality rate where roughly half of sufferers are unaware they have it and holds FDA 510(k) clearance for the US market. A second product, EchoSolv HF, addresses heart failure, a far larger clinical and commercial opportunity, and is under active FDA review. The investment case rests on four legs: a validated technology with published performance data, a regulatory pathway already open for one product and advancing for a second, a US commercial engine now being assembled through partnerships and capital, and — following the Advara deal — a proprietary data foundation to feed future products. The company is led by CEO Dustin Haines, a US-based executive who joined from Gilead Sciences, alongside Executive Chair Andrew Grover. The Placement: Terms and Use of Funds The placement will issue 75,862,069 new fully paid ordinary shares at A$1.45 each, representing approximately 11.5% of Echo IQ's current issued capital and raising close to A$110 million. The price sits at an 8.8% discount to the company's last traded price on 26 June - implying a last close of roughly A$1.59 - a comparatively tight discount for a raise of this size and a reflection of the strength of the bid. Settlement is scheduled for Monday 6 July, with the new shares expected to begin trading on Tuesday 7 July, ranking equally with existing shares. Ord Minnett acted as sole lead manager and Morgans as co-manager. The company has framed the use of funds around commercial acceleration rather than survival. Net proceeds are earmarked to: strengthen the balance sheet; accelerate US commercial execution and expand deployment of EchoSolv across US health systems; continue product development and pursue complementary strategic opportunities; and fast-track development of a broader cardiovascular AI platform beyond the current suite. On an enlarged base of roughly 737 million shares, the placement price implies an indicative market capitalisation above A$1 billion — a figure that has moved sharply in recent weeks, with the stock reaching an all-time high on the day the Pro Medicus agreement was announced. The dilution to existing holders is real at around 11.5%, but the discount is modest, and the capital is directed at the commercial build-out the story requires. The Pro Medicus Partnership The 25 June agreement is the most strategically loaded of the three announcements. Pro Medicus is widely regarded as one of Australia's most successful healthcare technology companies and a global leader in enterprise imaging through its Visage platform, with mission-critical deployments across major US health systems and academic medical centres. Its decision to both invest in Echo IQ and act as a reseller is the kind of third-party endorsement that is difficult to manufacture, and it gives EchoSolv a potential route into an established enterprise customer network. The investment is structured as secured convertible notes, with the second tranche aligned to FDA clearance of EchoSolv HF — the company's single largest near-term catalyst. The key terms are summarised below. In April, Echo IQ had confirmed the deployment of EchoSolv AS into Mount Sinai Health System, a major healthcare network based in New York, United States. Table 1: Pro Medicus convertible notes — Key terms Item Details Instrument Secured unlisted convertible notes, secured over all group assets, with specific security over the aortic stenosis and heart failure algorithms. Initial subscription 10,000,000 notes at A$1 face value (A$10m). Second tranche Option for a further 10,000,000 notes (A$10m), exercisable within 12 months of FDA clearance of EchoSolv HF; Pro Medicus is not obliged to proceed. Interest 12.5% per annum, compounding daily, payable at maturity. Maturity 24 months from issue; no voluntary prepayment permitted. Conversion Lower of a A$1.05 valuation cap or the 5-day VWAP at the time of conversion, subject to a floor (minimum 1,000,000 notes per conversion). Options 0.75 unlisted options per note, exercise price A$1.35, expiring 24 months from note issue. Approval Issued under ASX Listing Rule 7.1 placement capacity; no shareholder approval required. Two features warrant attention. First, the arrangement is a binding Heads of Agreement, not definitive documentation — the parties are still finalising legal terms, and Pro Medicus is not obliged to fund the second A$10 million even if FDA clearance is obtained. Second, the A$1.05 conversion cap sits well below both the A$1.45 placement price and the levels at which the stock has recently traded, meaning any conversion would occur at a discount to market and could dilute existing holders more than the headline numbers suggest. Neither point undoes the strategic value of the partnership, but both belong in a clear-eyed reading of the terms. The Advara Data Licence and the AI Moat On 2 July, Echo IQ executed a definitive exclusive data licensing agreement with Advara HeartCare, Australia's largest private cardiovascular diagnostics provider. Advara runs a national network of cardiology clinics supporting more than 750,000 patient interactions a year, and the agreement gives Echo IQ exclusive access to between 500,000 and 1,000,000 de-identified echocardiography studies - imaging together with linked clinical information such as referral pathways, diagnostic findings and outcomes — sourced from that network. The initial term is three years, with an option to extend for a further three, and the agreement includes IP protections under which Echo IQ retains ownership of all AI outputs. The strategic logic is about defensibility rather than immediate revenue. Echo IQ frames the Advara licence as complementary to its existing National Echo Database Australia (NEDA) relationship: NEDA provides one of the world's largest longitudinal cardiovascular outcomes datasets, central to clinical validation and regulatory evidence, while Advara supplies the large-scale real-world imaging data best suited to training and refining AI models. Together, the company argues, the two assets span the full pipeline from product discovery and algorithm development through validation to deployment - a proprietary, difficult-to-replicate data foundation as cardiovascular AI moves from single-disease tools toward multi-condition platforms. The exclusivity is doing real work here: it is as much about denying competitors the data as about feeding Echo IQ's own pipeline. The important qualifier is that this is a foundation for future products, not current ones. Initial delivery is conditional on Advara securing Human Research Ethics Committee (HREC) approval and the parties agreeing data-quality specifications; Advara has warranted a floor of 500,000 studies with at least 70% meeting those specifications, and if approval or specifications are not settled within 60 days of commencement, Echo IQ may terminate and recover its licence fees. The value of the asset therefore depends on both the data arriving as expected and Echo IQ converting it into cleared, commercialised algorithms over time. The Commercial and Regulatory Engine Behind the capital and the data sits the operating story. EchoSolv AS has held FDA 510(k) clearance since late 2024, supported by validation work including a Harvard Beth Israel study of more than 31,000 patients (Figure 2) EchoSolv HF is the larger prize: heart failure is one of the most expensive conditions in US healthcare, only around half of cases are accurately diagnosed, and Echo IQ's heart-failure model was independently validated through the Mayo Clinic Platform's Validate program, reporting sensitivity of 99.5% and specificity of 91.0% across roughly 17,000 patient echocardiograms. That study cleared the final clinical hurdle before the FDA submission, whose outcome the company expects in the near term. The Mayo Clinic relationship has since broadened into a distribution pathway, with an expanded agreement enabling Mayo to resell and distribute EchoSolv HF following clearance, alongside a separate cardio-oncology research collaboration. Layered on top are integrations reaching US cardiology networks and deployments into health systems including Mount Sinai. The Pro Medicus reseller arrangement, if it completes, would add a further enterprise channel. The through-line is consistent: Echo IQ is assembling recognised US distribution partners ahead of the EchoSolv HF decision, so that a clearance can be converted into deployment rather than merely announced. Figure 2: EchoSolv AS and Cardiologists (Source: EIQ Website) Management Commentary CEO Dustin Haines framed the placement as a step-change in the company's commercial phase. “This Placement represents the next step in Echo IQ's commercial evolution and reflects the strong strategic progress the Company has delivered over recent years,” he said, Pointing to FDA clearance of EchoSolv AS, expansion across US health systems, and partnerships with organisations including Mayo Clinic and Pro Medicus. He added that, following completion of the placement, the company expects to accelerate deployment of EchoSolv across the US, expand its commercial organisation and increase implementation capacity at a time when customer engagement continues to build. On the Pro Medicus agreement, Haines described a milestone that extends well beyond the money. “The execution of this binding Heads of Agreement with Pro Medicus represents a transformational milestone for Echo IQ and a significant validation of both our technology and long-term commercial strategy,” he said. He characterised the arrangement as an opportunity to leverage an established healthcare platform, trusted customer relationships and an experienced commercial organisation with deep US penetration, aligning Pro Medicus's participation with FDA clearance of EchoSolv HF as one of the company's most significant potential value catalysts. On the Advara licence, Haines positioned the dataset as a long-term capability rather than a near-term product, noting that while NEDA remains a world-class platform for clinical validation and outcomes research, the Advara imaging data brings “something different and highly complementary” that can be used to train and develop future generations of cardiovascular AI. Advara CEO Dr David O'Donnell framed the collaboration within his organisation's research mission, noting that appropriately governed and de-identified real-world data can support the responsible development of technologies designed to improve patient care. Samso Concluding Comments These three announcements is showing that this is a company executing on every front at once. In eight days, Echo IQ has secured the capital to fund its US push, the endorsement of a blue-chip healthcare-imaging partner, and exclusive access to one of Australia's largest cardiovascular imaging datasets. Funded, validated and building a proprietary data moat, it has removed the balance-sheet question from the EchoSolv HF catalyst and strengthened its long-term competitive position - and the market has rewarded the progress, with the shares among the ASX's best performers this year. Readers need to resist treating the news intent as banked value. The Pro Medicus arrangement is a Heads of Agreement, not definitive documentation, and its convertible-note terms - a A$1.05 conversion cap below market, a 12.5% compounding coupon, options at A$1.35 - carry a real dilution cost. The Advara dataset is conditional on ethics approval and yet to be delivered, and data access is a foundation for future products, not proof of them. After a fivefold re-rating, much of this optimism is already in the price. The strategy is sound, and the assets are real, but the value now turns on execution the company does not yet fully control: the FDA's decision on EchoSolv HF, the delivery and conversion of the Advara data, and the translation of validated technology into recurring US revenue. The pieces are in place; the proof is still ahead. The share price is definitely indicating a path to success and I cannot ignore the fact that since Samso started covering the EIQ story, the share price has almost done a 10 bag. Will this mean that it will continue or be a sign of some profit taking, that is a question that needs to be asked. I strongly suggest DYOR. The Samso Way – Seek the Research Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story. Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity. Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms: Coffee with Samso Samso Insights Samso News There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals. Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete. The Samso Philosophy: Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value. In Life, there is no such thing as a Free Lunch. Never bite off more than you can chew is my parting comment. Happy Investing, and the only four-letter word you need to know is DYOR. To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiative for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018. Disclaimer The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints. Read full Disclaimer. Share to Grow: Your Bonus Samso has just released an eBook: How to Add Value to your Share Portfolio |A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.| Download eBook If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au. About Samso Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insigh0ts from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research. Samso News | www.samso.com.au | An Investor Lens on ASX-Listed Companies

Samso News | Perth, Western Australia | Reference: CSIRO, International Symposium on Mafic-Ultramafic Mineral Systems 2026 The world's best minds in magmatic ore deposits just spent a week in Perth. Most ASX investors never heard about it and yet their portfolios are built on the science discussed in that room. ISMUMS2026 covered the mineral systems behind Ni, Cu, Co, PGEs, V, Ti and Cr: the metals of the energy transition, and the bread and butter of the ASX junior sector. Samso's job is to carry that knowledge across the gap as research, not promotion, for investors who want to understand the story beneath the announcements. Samso News Research Note Depth Not Hype Understanding Samso Introduction This week in Perth, some of the world's leading minds in magmatic ore deposits gathered at the International Symposium on Mafic-Ultramafic Mineral Systems 2026 (ISMUMS2026), hosted by CSIRO from 29 June to 3 July. Most ASX investors have never heard of it. That gap between where the science lives and where the investment decisions are made is precisely the space in which I feel is lacking in the market. ISMUMS2026 is the latest in a series of conferences that stretches back more than 50 years. Thirty meetings have been held across Canada, Australia, the United Kingdom, the United States, Russia, China, Finland, Zimbabwe and South Africa, historically alternating between the International Ni-Cu Symposia and the International Platinum Symposia. Over the decades the two themes have converged, and the 2026 meeting in Perth encompassed all mineral systems associated with mafic and ultramafic rocks, with a prime emphasis on the platinum group elements. Three days of talks were interwoven with two days of field trips, alongside the Wager and Brown Layered Intrusion Workshop. The commodities at the centre of the program read like a strategic shopping list for the energy transition: nickel, copper, cobalt, PGEs, vanadium, titanium and chromium. These are the metals governments are scrambling to secure, and the metals a large slice of the ASX junior sector is out there trying to find. The Science Is the Playbook Here is the thing most investors miss, and that is the science discussed at conferences like ISMUMS is not academic wallpaper. It is the playbook for where the next generation of discoveries will come from. It is also the critical asset in the playbook for making the right investments in a sector that is renown for being compared to a casino. The models of how magmatic sulfide systems form, where PGEs concentrate in layered intrusions, why some komatiite belts deliver Kambalda-style nickel and others deliver nothing, this is the knowledge that separates a well-targeted drill program from an expensive lottery ticket. Every exploration model an ASX junior presents to the market is, whether stated or not, a hypothesis built on this body of science. The quality of that hypothesis determines the quality of the drill targets, and the quality of the drill targets determines what shareholders' money is actually buying. There will be investors that say that they don't need to know the detail, they just want to know who is going to run the share price upwards. This is not untrue and this is also one way of making money, however, for honest investors, the investors or the participants of the casino that actually share the occurrences of a losing bet, the sure bets that is commonly shared in the market space, rarely gets it right. The researchers speak in mineral systems, sulfur saturation and chalcophile element behaviour. The market speaks in announcements, intercepts and share prices. Between the two sits the retail investor. And that is the translation problem. The people who understand how these deposits form rarely write for investors. The people who write for investors rarely sit in the room when the science is presented. Between the two sits the retail shareholder, trying to work out whether the company they hold actually understands the geology it is drilling. Where Samso Fits - Independent Research That translation gap is where Samso (www.samso.com.au) does its work. Samso is an independent research media house producing depth-led video and written content on ASX-listed companies. The philosophy is simple and, frankly, unfashionable: we do not promote, we research. We do not simplify for effect, we explain for understanding. When Samso sits down for a Coffee with Samso conversation with a managing director, or publishes an Insight on a nickel, PGE or critical minerals explorer, the aim is to ask the questions a geologist would ask. The main reason why Samso is a good read is because the analysis comes from someone who has logged core, walked the ground and sat on the company side of the table. What is the mineral system? What does the geochemistry actually say? Is the exploration model consistent with what the science community — the ISMUMS community — understands about how these deposits form? Those are not gotcha questions. They are the questions any institution with an in-house geologist asks before committing capital. Samso's role is to ask them in public, on the record, in language an investor can use — and to let readers draw their own conclusions from the answers. Three Reasons This Matters 1. The ASX is where these bets are placed. The ASX hosts the world's deepest pool of junior explorers hunting exactly the commodities ISMUMS2026 was built around. If you invest in this end of the market, you are, whether you realise it or not, making bets on mafic-ultramafic mineral systems. Knowing how those systems work is not optional context; it is the substance of the investment case. 2. Information asymmetry is the retail investor's biggest handicap. Institutions have in-house geologists who can interrogate an exploration model before a dollar is committed. Most retail investors have a two-page announcement and a social media feed. Independent, depth-led research does not eliminate that gap, but it narrows it — and narrowing it changes the quality of the decisions that follow. 3. Credibility compounds. Samso's value to the companies it covers comes from the trust it builds with readers — not the other way around. That is the model of an editorial charter, not a promotion mill. Content built to inform holds its value long after content built to excite has been forgotten, and an audience that trusts the analysis is worth more to everyone — company, investor and publisher — than an audience that has merely been reached. Samso Concluding Comments The green revolution will be built on the metals discussed in Perth this week. The companies that find them will mostly be listed on the ASX. And the investors who do best will be the ones who understand the story beneath the announcements — the mineral system, the geochemistry, the exploration logic — not just the headline intercept. To put in simply, investors should know to a degree that the "story" has some chance of being correct. That is the research Samso produces: independent, geology-literate, and written for the investor who wants to build a case rather than chase a narrative. Events like ISMUMS2026 are a reminder that the knowledge exists. The job of a research media house is to carry it across the gap. If you invest in ASX resources, www.samso.com.au is where that translation happens. Disclaimer: This article is a perspective piece produced by Samso for general information purposes only. It does not constitute financial product advice and has been prepared without taking into account the objectives, financial situation or needs of any individual. References to ISMUMS2026 are drawn from publicly available conference information published by CSIRO. Readers should conduct their own research and seek independent professional advice before making any investment decision. Samso may receive fees from companies it covers; its editorial content is prepared independently of any such arrangements. The Samso Way – Seek the Research Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story. Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity. Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms: Coffee with Samso Samso Insights Samso News There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals. Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete. The Samso Philosophy: Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value. In Life, there is no such thing as a Free Lunch. Never bite off more than you can chew is my parting comment. Happy Investing, and the only four-letter word you need to know is DYOR. To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018. Disclaimer The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints. Read full Disclaimer. If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au. About Samso Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insigh0ts from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research. Samso Insights | www.samso.com.au | An Investor Lens on ASX-Listed Companies

The company recasts the board and executive team with Sierra Rutile Veterans as the Minta Rutile & Monazite Project Pushes Toward a Maiden Mineral Resource Estimate Lion Rock Minerals Limited (ASX: LRM), formerly Peak Minerals, announced one of the more striking leadership reshuffles seen on the small-cap mineral sands board this year, installing two former Sierra Rutile executives — Theuns de Bruyn as Chief Executive Officer and Grant Scott as Chief Operating Officer. In addition, the board will be bolstered by Duncan Craib, the former Boss Energy MD, alongside David Brophy, a West African Licensing Expert, as Non-executive directors. The reshuffle is bookended by a $2 million cornerstone placement at $0.02 per share and a clear roadmap toward a maiden Mineral Resource Estimate at the Minta Rutile & Monazite Project in the second half of 2026.- supported by the incoming directors and executives. Lion Rock has been somewhat quiet in the last 12 months, and while they have in the past presented a compelling story for their project in Cameroon, the company has been very shy in their communication with the market. The recent ASX release seems to be announcing a clear message to the market that Lion Rock is back to play again. A SIERRA RUTILE REUNION, TRANSPLANTED TO CAMEROON The central narrative has not changed since Samso started covering Lion Rock Minerals and this is a deliberate recreation of a Sierra Rutile-style operating model at Minta. Mr de Bruyn and Mr Scott previously worked together at Sierra Rutile Holdings Limited — then the world’s largest natural rutile producer — and between them carry more than 60 years of experience across project development, feasibility, financing, in-country operations and product marketing in the African mineral sector. Figure 1: The new Board and Executive team at Lion Rock Minerals (Source: Samso, compiled from LRM ASX announcement, 21 May 2026). Mr de Bruyn’s background spans host-government engagement, communities, and international development finance institutions. Mr Scott’s technical remit at Sierra Rutile covered surveying, mine planning, resource and reserve estimation, geotechnical and geological drilling, rehabilitation, water and tailings management, reconciliations and feasibility studies. Both CEO and COO will be based in-country in Cameroon for the duration of the Minta Project’s development phase. That pairing is now bolted onto a board led by Duncan Craib, whose recent career arc took Boss Energy Limited (ASX: BOE) from a microcap Australian holding company to an international ASX 200 uranium producer, and who served as Finance Director at Swakop Uranium during its US$2.2 billion corporate takeover and US$2.5 billion development of the Husab mine in Namibia, becoming one of the world’s largest uranium producers. Mr Craib also chaired the Uranium Forum of the Minerals Council of Australia from September 2021 to August 2025, and has successively overseen two international uranium projects through their growth phases into producing assets with worldwide sales distribution. He visited Cameroon twice before accepting the chairmanship — first as a guest to inspect the projects, and again with Mr de Bruyn and Mr Scott to undertake due diligence on the ground, including meetings with senior representatives of the Cameroonian Minister of Mines, Industry and Technological Development. David Brophy joins the Board as Non-Executive Director and is, in his own way, as deliberate a piece of the new structure as the Sierra Rutile pairing. His 20+ years of commercial experience spans West and Central African commodity supply chains, risk management, derivative hedging, and client-focused distribution across global markets. His career has run through senior roles at ECOM, Noble Group and Glencore Grain BV, where he contributed to the establishment of global cotton trading desks in Singapore and Rotterdam. Since returning to Australia, Mr Brophy has opened and developed West and Central African procurement operations across Mali, Burkina Faso, Benin, Ivory Coast and Cameroon — the latter being the jurisdiction in which Minta sits. He operates a resources consulting business assisting mining companies with licensing matters in West Africa, alongside a cotton procurement and logistics business focused in the region, and is the founder of Mansa Carbon, a project developer active in the Voluntary Carbon Market in West Africa. From a project assessment perspective, the Brophy appointment fills a specific gap. Where Mr Craib brings uranium-development and capital-markets pedigree, and Messrs de Bruyn and Scott bring the rutile-mining technical and operating pedigree, Mr Brophy brings the commercial, supply-chain and licensing relationships across West and Central African jurisdictions — specifically including Cameroon — that an asset like Minta will require as it progresses from exploration into permitting, offtake structuring and eventual product marketing. That is a useful complement to a board whose other appointees are concentrated on the technical and corporate dimensions of the story. Outgoing directors Robert Boston and Phillip Gallagher retire from the Board with immediate effect. The Board acknowledged Mr Gallagher’s particular contribution in identifying and securing the province-scale rutile and monazite opportunity at Minta — the initiative that established the foundation on which the Company’s next phase is being built — and thanked Mr Boston for his contribution to the Company’s formation and governance over the last nine years. The structural decision that matters here is the relocation of both the CEO and COO to Cameroon for the development phase. The 14 March 2026 management update flagged that the prior Board had concluded a greater in-country presence was needed to advance exploration and development at Minta. The new appointments deliver that change in literal form — not just senior oversight, but day-to-day technical decision making, government engagement and operational control located alongside the asset. The team has started preliminary work while visiting the project on that second visit. The incoming team inspected active drilling areas, reviewed the in-country laboratory facility being commissioned to support field sampling, and visited Minta Est, where field panning and visual inspection had indicated the presence of heavy minerals including rutile, ilmenite, zircon and monazite. The team also met with senior representatives of the Cameroonian Minister of Mines, Industry and Technological Development. Management Commentary — The Strategic Context “Our Minta Project is attracting world-wide attention for its significant and growing resource base of rutile and monazite.” — Duncan Craib, Incoming Non-Executive Chair, Lion Rock Minerals Limited (21 May 2026) “Lion Rock’s Minta Project has the hallmarks of a globally significant rutile and monazite producer.” — Theuns de Bruyn, Incoming Chief Executive Officer, Lion Rock Minerals Limited (21 May 2026) THE MINTA RUTILE & MONAZITE PROJECT — THE ASSET THAT JUSTIFIES THE RESET The Minta Rutile & Monazite Project is Lion Rock’s flagship asset, comprising 18 granted exploration permits and three further permits under valid application across approximately 8,800 km² of prospective ground in central Cameroon, with the 21 May 2026 announcement describing approximately 5,000 km² of prospective ground in the higher-priority belt within that footprint. Lion Rock holds an 80% group interest in each of the Minta tenements. Mineralisation styles include the residual concentration of valuable heavy minerals — monazite, rutile and zircon — in deflated soils across elevated terrain, alongside the concentration of valuable heavy minerals and gold in large-scale alluvial basins. In-situ vein-hosted gold has been artisanally mined and mapped and sampled by the Company and remains under consideration for focused exploration. A short Samso primer on the heavy minerals at Minta Rutile is the principal natural form of titanium dioxide (TiO₂) and the highest-grade titanium feedstock used in the production of titanium pigment, titanium metal and welding fluxes. Natural rutile typically carries a TiO₂ content above 90%, which is why integrated producers like Tronox value direct access to rutile feedstock streams. Monazite is a rare-earth-bearing phosphate mineral, typically rich in light rare earth elements (cerium, lanthanum, neodymium, praseodymium) but also carrying a measurable component of heavy rare earths via the coexistence of xenotime. Monazite-rich heavy mineral concentrates are an established feedstock for rare-earth processing routes. Valuable Heavy Mineral (VHM) is the industry shorthand for the saleable portion of a heavy mineral assemblage — in the Minta context, that means rutile, zircon and monazite. The "dual residual–alluvial" strategy that Lion Rock has flagged is essentially a recognition that both the in-situ residual soils and the downstream alluvial basins can host economic VHM concentrations. Heavy-liquid separation (HLS) is a laboratory technique that uses a dense fluid to physically separate heavy minerals (rutile, monazite, zircon, ilmenite) from lighter gangue minerals. Bringing HLS in-country at the Yaoundé laboratory materially compresses the loop between drilling, mineralogical interpretation and product qualification work. Geologically, the central Cameroon rutile system is interpreted to have crystallised from the scavenging of titanium-bearing units from sediments subjected to high temperatures and pressures during regional metamorphism. At least two generations of granite intrusion have introduced fluids and heat that remobilised gold and introduced monazite and zircon at Minta Est. The coarse rutile crystals identified across broad areas indicate the late emplacement of a broad-scale pegmatite vein system — and large angular rutile nuggets identified in recent and historical sampling programs have the potential to materially boost total Valuable Heavy Mineral grade in residual and alluvial prospects. Zones of very high-grade zircon mineralisation have also been identified at Minta Est, alongside alluvial and hard-rock gold occurrences across the northeastern tenement area coincident with a geophysical anomaly associated with granitic intrusions. Figure 2: The Company’s flagship Minta Rutile and Monazite Project in Cameroon (Source: LRM ASX announcement, 21 May 2026). The infrastructure setting matters for any West or Central African development story — and the incoming team was specific about its endorsement of what it found. The 21 May 2026 announcement described the regional infrastructure setting as featuring maintained road access, nearby rail connections via the Nanga Eboko rail line, power supply and internet access, all of which contribute to the project’s development pathway. Mr de Bruyn extended that view to the country itself. “The country is more organised, connected and capable of supporting mining development than many outside observers might expect.” — Theuns de Bruyn, on the Cameroon operating environment (21 May 2026) Strategic Partnership with Tronox Sitting behind the operational restructure is an existing relationship with Tronox Holdings plc (NYSE: TROX), an integrated producer of titanium dioxide with US-government endorsement of its proposed rare earth refinery. Tronox has already secured a 5% interest in Lion Rock and has identified Minta as a potential feedstock source for its rare earth strategy. The 21 May 2026 announcement frames the partnership as focused on accelerating the Minta Project and aligning with Tronox’s strategy to secure end-to-end rare-earth supply chains. From a project assessment perspective, this is the strategic feature of the Minta story that most distinguishes it from the rest of the ASX rutile small-cap field. A NYSE-listed integrated TiO₂ producer with declared rare-earth ambitions does not put 5% on a register without an operational thesis. Whether that thesis converts into a formal offtake or a deeper equity move over the next twelve months is one of the structural questions overhanging the Minta story. OPERATIONAL TEMPO During the March 2026 quarter, Lion Rock completed 681 holes for 3,310 metres of infill drilling at high-value rutile targets across the wider Minta Project. A focused 299-hole, 1,281-metre infill program was also completed at Minta Est over the ~250 km² monazite-enriched granite that the Company has identified as the source of monazite, xenotime and zircon coincident with high-grade rutile zones. Figure 3: Ongoing infill drilling activities at Minta Est (Source: LRM March 2026 Quarterly Activities Report, 28 April 2026). On the assay side, further high-grade rutile results received during March 2026 confirmed in-situ rutile grades of up to 2.6% from residual targets, with multiple locations returning at or above 1.0% rutile and a broader population at or above 0.5%. Standout intercepts included up to 4 metres at 1.8% rutile from residual drilling. Results spanned both residual and alluvial settings, supporting the Company’s dual residual–alluvial development strategy across a >5,000 km² footprint, with key alluvial corridors — including the Yong river basin — flagged as priority follow-up targets. Figure 4: Minta Est infill drilling coverage on thorium radiometrics as at January 2026, with monazite assemblage results from completed drill holes (Source: LRM March 2026 Quarterly Activities Report). The spatial context of the Minta Est infill is what makes the program material. The Company’s January 2026 drilling coverage map (Figure 4) shows the infill drill pattern superimposed over thorium radiometrics, with individual completed drill holes labelled with their monazite assemblage percentages — ranging from the 1.9% recorded at ME22S07 up to a standout 73.7% monazite assemblage at ME22S04. The high-monazite-assemblage holes (ME22S04, ME22S03, RE1028 and RE0014) cluster within the granite footprint that the Company has identified as the local source of monazite, xenotime and zircon, providing the geological basis for the dual residual–alluvial development strategy. Table 1: Selected heavy mineral results from Minta and Minta Est (Source: LRM March 2026 Quarterly Activities Report) Drill hole / Location Mineral / Metric Value Context ME22S04 Monazite assemblage 73.7% Minta Est, monazite-enriched granite domain ME22S03 Monazite assemblage 40.0% Minta Est, central granite domain RE1028 Monazite assemblage 37.2% Minta Est, residual target RE0014 Monazite assemblage 35.6% Minta Est, residual target ME22S02 Monazite assemblage 25.1% Minta Est, granite domain ME22S01 Monazite assemblage 18.0% Minta Est, southern granite domain ME22S05 Monazite assemblage 14.3% Minta Est, eastern granite domain RE0018 Monazite assemblage 12.5% Minta Est, residual target ME22S07 Monazite assemblage 1.9% Minta Est, granite margin Residual targets — multiple Peak in-situ rutile Up to 2.6% Multiple locations ≥ 1.0% rutile Residual drilling — standout In-situ rutile intercept 4 m @ 1.8% Wider Minta high-value targets Monazite assemblage values represent the percentage of monazite within the heavy mineral assemblage at the labelled drill holes as published in the Company’s January 2026 coverage map (Figure 4). In-situ rutile results refer to grades published in the Company’s 18 March 2026 release. Assays from the broader 299-hole Minta Est program and the 681-hole rutile program were pending at the time of the March 2026 Quarterly Activities Report. From a project assessment perspective, the most important spatial outcome of the March quarter is the demonstration that the monazite-enriched granite at Minta Est is locally sourcing the heavy mineral assemblage. The presence of coarse, angular monazite crystals in residual soils — with limited transport — reinforces the case for both residual concentration in deflated high-ground domains and alluvial accumulation in downstream basins. That dual style is what underpins the maiden Mineral Resource Estimate workflow now in train. Laboratory and Mineralogical Workstreams The Yaoundé in-country laboratory — currently being commissioned with heavy-liquid separation capability — is one of the more underrated structural decisions in the recent operating playbook. It is designed to support ongoing assay prioritisation, mineral assemblage studies and future process flowsheet design while reducing reliance on offshore sample preparation and allowing faster iteration between drilling and mineralogical interpretation. For an exploration program built around throughput and a maiden MRE target in H2 2026, that turnaround time matters. Path to the Maiden Mineral Resource Estimate Pending assays from the 299-hole Minta Est program and the broader 681-hole rutile program are expected to feed into geological modelling and resource estimation workflows during H1 2026, with the maiden Mineral Resource Estimate targeted for H2 2026. The Company has framed the next twelve months as the value-defining exploration phase — a phrase that captures the fact that the market does not yet have a JORC-compliant resource against which to value the district-scale story. Figure 5: Minta at a glance — March 2026 quarter operating metrics, Placement structure, and the 6–12 month milestone roadmap (Source: Samso, compiled from LRM ASX announcement of 21 May 2026 and LRM March 2026 Quarterly Activities Report). THE $2 MILLION CORNERSTONE PLACEMENT — FUNDING THE NEXT PHASE Lion Rock has received firm commitments to raise $2 million through a placement of 100 million new shares at $0.02 per share, conducted under the Company’s existing placement capacity pursuant to ASX Listing Rule 7.1A. New shares rank equally with existing shares on issue. The Placement was cornerstoned by the incoming directors and executives, and supported by a limited number of known and respected industry professionals. Following settlement, the Company will have a pro forma cash position of approximately $8 million (comprising the $2 million capital raise plus existing cash reserves of $6 million as at 15 May 2026). Placement funds are earmarked for ongoing exploration at the Minta Project, business development activities and general working capital. The pro forma quarters of funding at the March 2026 burn rate (~A$1.26m on exploration during the quarter) would extend the Company’s runway well beyond the targeted maiden MRE date. Incoming Team Incentive Package Under the terms of the agreements with the new leadership team, the Company has agreed to issue a total of 270 million unquoted options structured as follows: Table 2 : Incoming Team Incentive Package Tranche Quantity Exercise Price Expiry Incoming team — Tranche A 135,000,000 options $0.03 3 years from issue Incoming team — Tranche B 135,000,000 options $0.04 3 years from issue CEO incentive (de Bruyn) — Tranche A 30,000,000 options $0.03 21 May 2029 CEO incentive (de Bruyn) — Tranche B 30,000,000 options $0.04 21 May 2029 Source: LRM ASX announcement, 21 May 2026. The CEO incentive options form part of the Company’s Employee Securities Incentive Plan. Mr de Bruyn’s contract carries an annual salary of A$450,000 with a three-month probationary period (one-month termination notice during that period) and a three-month termination clause thereafter. Table 3: Capital Structure (at 31 March 2026 quarterly) Security Number on issue Ordinary fully paid shares 3,463,917,147 Ordinary fully paid shares — escrowed to 7 July 2026 100,000,000 Unquoted options @ $0.005 (exp. on/before 25 Sept 2027) 90,000,000 Unquoted options @ $0.0165 (exp. on/before 10 Feb 2028) 40,000,000 Unquoted options @ $0.020 (exp. on/before 10 Feb 2028) 40,000,000 Unquoted options @ $0.0165 (exp. on/before 9 May 2028) 46,600,000 Source: LRM March 2026 Quarterly Activities Report. The 21 May 2026 announcement adds a further 100 million new ordinary shares (Placement) and 270 million unquoted options to the incoming leadership team upon settlement and issue. OTHER PRIJECTS - KITONGO AND LOLO URANIUM PROJECTS — THE URANIUM OPTIONALITY Beyond Minta, Lion Rock retains the Kitongo and Lolo Uranium Projects in Cameroon. The Kitongo Uranium Project spans approximately 2,200 km² across five tenements in the northwest Adamoua Province; the Lolo Project covers approximately 240 km² across one tenement in the South region, approximately 70 km southwest of Yaoundé and 111 km from the Kribi deep-water port. All six tenements are currently pending grant. Figure 6: Location map of the Kitongo and Lolo Uranium Projects ( Source LRM Website) Prospectivity for uranium has been confirmed by significant historical exploration, initially in the 1970s and more recently between 2007 and 2011, when systematic exploration by Mega Uranium Ltd (TSX: MGA) — following its CAD150 million acquisition of Nu Energy Corporation in April 2007 — produced encouraging results from drilling programs undertaken in 2008 and 2010. During March 2009, Mega Uranium released results from an 11-hole diamond drilling program at Kitongo that indicated the presence of high-grade uranium mineralisation; in 2010, Mega Uranium completed a diamond drilling program at Lolo that tested a small portion of the 80 km-long prospective uraniferous belt and confirmed the presence of high-grade uranium mineralisation. During the March 2026 quarter, the Company continued working with uranium competent person Dr Marat Abzalov to design upcoming exploration programs while awaiting finalisation of the permitting process. The Company has explicitly noted that it has not been able to verify any of the historical drill intercepts and treats them as indicative only, pending confirmation drilling. From a project assessment perspective, the most interesting feature of the 21 May restructure is that Lion Rock now has — for the first time — a chairman with a direct uranium-development track record sitting above an asset that, on its face, looks like classic uranium-developer optionality. Mr Craib’s Boss Energy (ASX: BOE) and Swakop Uranium experience aligns directly with the kind of work program that Kitongo and Lolo will need once the permits are granted. That alignment is one of the quietly notable features of the May 21 restructure. PORTFOLIO HOUSEKEEPING — GREEN ROCKS DIVESTED The March 2026 quarterly also recorded the agreement to divest the Green Rocks Project tenements in Western Australia to Meekatharra Minerals East Pty Ltd (an unrelated party) by way of the sale of 100% of the shares in Greenrock Metals Pty Ltd and CU2 WA Pty Ltd for A$100,000 each (A$200,000 total). Completion occurred in April 2026. The Company determined the tenements to be non-core given their holding costs and minimal planned future work — a tidy-up that simplifies the corporate story ahead of the new team’s arrival. The Yendon Kaolin Project in Victoria (four licences in the Ballarat-Bendigo zone of the Lachlan Fold Belt) remains, with desktop review activities continuing during the quarter. NEAR-TERM MILESTONES TO WATCH Reading the 21 May 2026 announcement and the March 2026 Quarterly Activities Report side-by-side, the following near-term milestones have been disclosed across the two source releases: Table 4: Near-term milestones for Lion Rock Minerals Activity Timing Status / Source Settlement of $2m Placement (100m shares @ $0.02) Following 21 May 2026 announcement Firm commitments received; Placement under ASX Listing Rule 7.1A (21 May 2026 release) Issue of 270m unquoted options to incoming team On commencement 135m @ $0.03 and 135m @ $0.04; all 3-year expiry (21 May 2026 release) Cornerstone in-country relocation — CEO and COO Effective immediately Both based in Cameroon for the development phase (21 May 2026 release) Assays from 299-hole Minta Est infill program Q2 2026 1,281 m drilled over the monazite-enriched granite; assays pending (March 2026 quarterly) Assays from broader 681-hole, 3,310 m rutile program H1 2026 Assays feeding into geological modelling and resource estimation workflows (March 2026 quarterly) In-country Yaoundé laboratory commissioning H1 2026 Heavy-liquid separation capability being commissioned (March 2026 quarterly) Maiden Mineral Resource Estimate at Minta H2 2026 Headline catalyst signalled by the Company (March 2026 quarterly; 21 May 2026 release) Kitongo & Lolo Uranium Projects — permitting Pending All 6 tenements currently pending grant (March 2026 quarterly) Upcoming uranium exploration program design Underway Working with competent person Dr Marat Abzalov (March 2026 quarterly) ABOUT LION ROCK MINERALS LIMITED Lion Rock Minerals Limited (ASX: LRM), formerly Peak Minerals Limited, is an Australian-listed mineral sands and critical minerals explorer focused on the development of its flagship Minta Rutile & Monazite Project in central Cameroon. The Company holds an 80% group interest in 18 granted exploration permits and three further permits under valid application across approximately 8,800 km² of prospective ground at Minta, with approximately 5,000 km² described as the higher-priority prospective belt within that footprint. Beyond Minta, Lion Rock holds the Kitongo and Lolo Uranium Projects in Cameroon (six tenements totalling approximately 2,440 km², all currently pending grant) and the Yendon Kaolin Project in Victoria (four licences in the Ballarat-Bendigo zone of the Lachlan Fold Belt). The Green Rocks Project in Western Australia was divested in April 2026 as non-core. Tronox Holdings plc (NYSE: TROX), an integrated producer of titanium dioxide with US-government endorsement of its proposed rare earth refinery, holds a 5% interest in the Company and has identified Minta as a potential feedstock source for its rare earth strategy. The Company’s strategic objective is to deliver a maiden Mineral Resource Estimate at Minta in H2 2026 under the operational direction of a newly appointed Sierra Rutile-pedigree executive team, with both the CEO (Theuns de Bruyn) and COO (Grant Scott) based in-country in Cameroon for the duration of the Minta Project’s development phase. The Board is chaired by Duncan Craib, the former Managing Director and CEO of Boss Energy Limited (ASX: BOE), with David Brophy as Non-Executive Director bringing 20+ years of commercial experience across West and Central African commodity supply chains, licensing and procurement. As at the March 2026 quarterly, Lion Rock reported A$6.872 million in cash and cash equivalents, with a pro forma cash position of approximately A$8 million following settlement of the $2 million Placement announced on 21 May 2026. The Company’s capital structure at 31 March 2026 comprised 3,463,917,147 ordinary fully paid shares on issue (plus 100 million escrowed) and 216,600,000 unquoted options on issue. SAMSO CONCLUDING COMMENTS Samso has been covering the Lion Rock Minerals story for a long. We have also been a shareholder of the story and have since exited the majority of the holdings; however, this new management brings a different complexion to the story. One of the biggest issues with Lion Rock Minerals is the high market capitalisation. At the current share price, Lion Rock Minerals is valued at AUD $92M. This kinds of scare real punters way and I have to say that at that valuation, there are safer bets in the market. However, does that mean that this is not an investable story for the average punter on the ASX? This is a unique situation of having what looks like a classy project, and it does have very good backers, long-term and very influential investors. I think there will be a revaluation coming soon, and the new team will be looking to move on from this valuation; I have no doubt. The time for the sleeping giant to wake up may be imminent. DYOR as always, but look seriously.

Miramar Resources Limited (ASX: M2R) Miramar Resources Limited (ASX: M2R) is a Western Australian-focused mineral exploration company that is actively exploring projects in the Eastern Goldfields and Gascoyne regions and was listed on the ASX in October 2020. The Company has three highly prospective projects in the Eastern Goldfields with the potential for new gold discoveries in proximity to existing mining and/or processing operations. Miramar also has two projects in the Gascoyne region: Whaleshark and Bangemall. The under-explored Capricorn Orogen region is highly prospective for gold, copper and nickel-copper-platinum group elements (Ni-Cu-PGE). The Company's Board has a track record of discovery, development and production within Australia, Africa, and North America. It aims to create shareholder value through the discovery of high-quality mineral deposits. Read More

OD6 Metals Limited (ASX:OD6) OD6 Metals Limited (ASX:OD6) is an Australian public company pursuing exploration and development opportunities within the critical minerals sector within Australian and the U.S. The Company has successfully identified clay hosted rare earths at its 100% owned Splinter Rock, located in the Esperance-Goldfields region of Western Australia – about 150km northeast of the major port and town of Esperance. OD6 Metals has recently secured an option to acquire the Quinn Fluorspar Project in Neveda, USA. In 1969, the United States Geological Survey (USGS) conducted a survey and confirmed fluorspar grading up to 72% CaF2 in bulk samples. The company is advancing the historic high grade Copper-Zinc Gulf Creek Mine in NSW. The copper-zinc mineralisation is connected with magnetite which shows repeat structures to the north and west of the mine with >10km of untested strike. Read More

Echo IQ Limited (ASX: EIQ) Echo IQ Limited (ASX: EIQ) is an Australian-based medical technology company focused on artificial intelligence solutions for cardiac diagnostics. The company’s core product is EchoSolv, an AI-driven decision support tool designed to assist clinicians in detecting structural heart disease using echocardiography. The technology aims to reduce misdiagnosis and improve clinical workflow efficiency. Echo IQ has achieved key regulatory milestones, including FDA clearance in the United States. The company is progressing commercialisation through strategic partnerships, including its collaboration with the Mayo Clinic. Echo IQ is positioning itself within the growing digital health and AI diagnostics sector, targeting improved patient outcomes and more efficient healthcare delivery. Read More